1 State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies.

2 Ethnic Differences in Hematologic Toxicity from Imatinib in Patients with Gastrointestinal Stromal Cell Tumor (GIST): Coincidence or a Real Phenomenon.

3 Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines

4 pathway-based analysis of genome-wide association data identified snps in hmmr as biomarker for chemotherapy- induced neutropenia in breast cancer patients

5 novel mutations in  the taz gene in  patients with barth syndrome

6 role of biosimilars in neutropenia prevention in cancer patients

7 the role of corticosteroids in adult respiratory distress syndrome caused by viridans group streptococci bacteremia in neutropenic patients

8 ultrasound for critical care physicians: a tempting dilemma

9 triagem para o tratamento ambulatorial da neutropenia febril screening for the outpatient treatment of febrile neutropenia

10 demam pada pasien neutropenia

11 predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer

12 medical image of the week: bronchial clot removal via cryotherapy

13 tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients

14 Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis

15 Long-term epidemiology of bacterial susceptibility profiles in adults suffering from febrile neutropenia with hematologic malignancy after antibiotic change

16 Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome

17 Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis

18 Long-term epidemiology of bacterial susceptibility profiles in adults suffering from febrile neutropenia with hematologic malignancy after antibiotic change

19 Parvovirus B19 infection presenting with neutropenia and thrombocytopenia: Three case reports.

20 Congenital neutropenia: diagnosis, molecular bases and patient management

21 Procalcitonin and C-Reactive Protein As Markers of Bacteremia in Patients With Febrile Neutropenia Who Receive Chemotherapy for Acute Leukemia: A Prospective Study From Nepal.

22 Impairment of G-CSF receptor on granulocytic progenitor cells causes neutropenia in protein malnutrition

23 Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study.

24 The Infectious Diseases Society of America 2002 Guidelines for the Use of Antimicrobial Agents in Patients with Cancer and Neutropenia: Salient Features and Comments

25 A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

26 Antibiotics in patients with neutropenia

27 Is monotherapy for febrile neutropenia still a viable alternative?

28 Microbial Translocation Contribute to Febrile Episodes in Adults with Chemotherapy-Induced Neutropenia

29 Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole

30 New trends in patient management: risk-based therapy for febrile patients with neutropenia

31 Economic Issues: Toward a Cost-Effective Approach to the Management of Febrile Neutropenia in Japan

32 Randomized Trial of Cefepime Monotherapy or Cefepime in Combination with Amikacin as Empirical Therapy for Febrile Neutropenia

33 Microbiological Data for Patients with Febrile Neutropenia

34 Multiplex Blood PCR in Combination with Blood Cultures for Improvement of Microbiological Documentation of Infection in Febrile Neutropenia

35 Antibiotics in Patients With Neutropenia

36 Microbial Translocation Contribute to Febrile Episodes in Adults with Chemotherapy-Induced Neutropenia

37 Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

38 Antimicrobial Prophylaxis in Febrile Neutropenia

39 Fungal infections in neutropenia: current problems and chemotherapeutic control.

40 Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

41 Fungal infections in neutropenia: current problems and chemotherapeutic control

42 Treatment of febrile neutropenia: what is new?

43 Evidence-Based Recommendations for Antimicrobial Use in Febrile Neutropenia in Japan: Executive Summary

44 Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia

45 Microbiological findings in febrile neutropenia

46 Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria

47 Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials

48 Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?

49 Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study

50 Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia

51 A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

52 "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia

53 [Clinical guide for the evaluation and treatment of patients with neutropenia and fever]

54 Multinational cooperation in trials and guidelines dealing with febrile neutropenia

55 Soluble c-kit ligand production by bone marrow stromal cells is independent of the degree of neutropenia in patients with chronic idiopathic neutropenia

56 Management of fever in patients with cancer and treatment-induced neutropenia

57 Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?

58 procalcitonin and interleukin-6 as markers of severe infection in children with febrile neutropenia

59 recurrent febrile neutropenia and thrombocytopenia in a chronic cocaine user: a case of levamisole induced complications

60 fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance—an asian perspective

61 chemotherapy-induced neutropenia in hiv positive patients with lymphoma: comparison of pegfilgrastim with daily filgrastim administration.

62 difference in neutropenia due to administration schedule of tas-102

63 economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in canada

64 SRP54 mutations induce congenital neutropenia via dominant-negative effects on XBP1 splicing

65 Interferon α–Enhanced Clearance of Group A Streptococcus Despite Neutropenia

66 Is It Safe to Use Long-Acting G-CSF for Febrile Neutropenia Prophylaxis in COVID-19 Pandemic?

Keyword Connections

Journals

Research Groups

Bibliographies